News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck KGaA (MKGAF.PK)'s Erbitux Fails in Colon Cancer Study


5/9/2012 8:31:31 AM

Germany's Merck KGaA said on Wednesday that Erbitux, one of its most important drugs, failed to help colon cancer patients after surgery in a late stage trial. A scheduled interim analysis of the so-called Petacc-8 study, which tested Erbitux in combination with standard chemotherapy as a treatment of colon cancer that has started spreading, showed no improvement in disease-free survival compared with using chemotherapy only. Merck's Erbitux competes with Amgen Vectibix in the market for certain colorectal cancer treatments and is also approved for treating head and neck cancer.

Read at Baltimore Sun
Read at RTT News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES